Results of colestipol therapy in Type II hyperlipoproteinemia.
Twenty-five patinets with well defined Type ii hyperlipoproteinemia were treated with a divided 15 g daily dose of colestipol, a bile acid sequestrant, for periods of up to 20 months. The patients were divided into 3 groups: Those with no obvious sequelae, those with arcus corneae, xanthomas, and/or xanthelasmas only, and those with atherosclerotic complications. Colestipol lowered plasma cholesterol in all 3 groups, but reduced it to normal or near-normal levels in only 9 of the 25 patients (36%). The response of plasma triglycerides was highly varible; the mean for each group was elevated by the drug. Colestipol was well-tolerated and its effect did not diminish with time. It is a useful drug in the treatment of hypercholesterolemia.
D000293:Adolescent; D000328:Adult; D001161:Arteriosclerosis / Q000097:blood / Q000188:drug therapy; D002648:Child; D002675:Child, Preschool; D002784:Cholesterol / Q000097:blood; D003084:Colestipol / Q000008:administration & dosage / Q000627:therapeutic use*; D004036:Diet, Atherogenic; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000178:diet therapy / Q000188:drug therapy*; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000235:genetics*; D008077:Lipoproteins, LDL / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D011073:Polyamines / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
D008077:Lipoproteins, LDL; D011073:Polyamines; D014280:Triglycerides; D002784:Cholesterol; D003084:Colestipol